Tresiba Side Effects: Severity Distribution by Patient Phenotype

What Is the Overall Adverse-Event Profile of Tresiba?

Tresiba's prescribing information lists hypoglycemia as by far the most frequent adverse reaction, with nasopharyngitis, upper respiratory tract infection, headache, and injection-site reactions appearing in at least 5% of patients in phase 3 trials. The FDA-approved label reports that in adult T1D trials, 80.5% of patients experienced at least one hypoglycemic episode over 52 weeks of treatment. In T2D trials that figure was 24.9% [1].

How Adverse Events Are Classified

The Tresiba label and trial publications stratify adverse events across three tiers:

• Confirmed hypoglycemia: blood glucose <56 mg/dL or requiring third-party assistance
• Severe hypoglycemia: requiring external assistance regardless of blood glucose value
• Non-hypoglycemic adverse events: injection-site reactions, allergic responses, systemic effects

This tiered structure matters clinically because many patients experience confirmed but non-severe episodes dozens of times per year without ever requiring emergency care. The downstream risks, including cardiac arrhythmias and cognitive impairment from repeated mild hypoglycemia, are nonetheless real.

What the FAERS Database Shows

A review of FDA Adverse Event Reporting System (FAERS) data through Q1 2024 shows hypoglycemia and hypoglycemic coma as the two most frequently reported serious outcomes for insulin degludec [2]. Injection-site lipodystrophy and allergic reactions each appear in fewer than 2% of spontaneous reports, consistent with the controlled-trial data. FAERS data are voluntary and subject to underreporting bias, so these rates represent a floor, not a ceiling.

Hypoglycemia: The Dominant Risk, Broken Down by Phenotype

Hypoglycemia is not a uniform risk. Its rate, severity, and time-of-day pattern differ meaningfully across patient subgroups. Choosing Tresiba over another basal insulin is often a phenotype-specific decision.

Type 1 Diabetes

Patients with T1D carry the highest absolute hypoglycemia burden on any basal insulin. SWITCH 1 (N=501, crossover design, 32-week treatment periods) compared insulin degludec U100 head-to-head against insulin glargine U100 in T1D patients. The confirmed hypoglycemia rate was lower with degludec: rate ratio 0.89 (95% CI 0.85 to 0.94, P<0.001). Confirmed nocturnal hypoglycemia showed an even larger separation, with a rate ratio of 0.63 (95% CI 0.57 to 0.70, P<0.001) [3].

These numbers translate into roughly one fewer confirmed hypoglycemic episode per patient per month in a population where 12 to 15 events per month is not unusual.

Type 2 Diabetes

SWITCH 2 (N=721, same crossover design) enrolled T2D patients on basal-bolus or basal-oral therapy. Confirmed hypoglycemia rate ratio for degludec vs. Glargine U100 was 0.70 (95% CI 0.61 to 0.80, P<0.001). Nocturnal confirmed hypoglycemia rate ratio was 0.64 (95% CI 0.53 to 0.78, P<0.001) [3].

Severe hypoglycemia events were too infrequent in SWITCH 2 to reach statistical significance in isolation, which is typical for T2D trials. The DEVOTE trial provided more power on that endpoint.

Cardiovascular Disease Phenotype

DEVOTE (N=7,637) was a cardiovascular outcomes trial comparing insulin degludec U200 against insulin glargine U100 in high-cardiovascular-risk T2D patients [4]. The trial met its non-inferiority endpoint for MACE (major adverse cardiovascular events): hazard ratio 0.91 (95% CI 0.78 to 1.06). Severe hypoglycemia was a pre-specified secondary endpoint. Degludec produced a 40% lower rate of severe hypoglycemia compared with glargine (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) [4].

The DEVOTE-3 sub-analysis found that severe hypoglycemia was independently associated with increased risk of all-cause mortality (hazard ratio 2.51, 95% CI 1.79 to 3.50) and cardiovascular mortality (hazard ratio 3.49, 95% CI 2.26 to 5.40) [5]. This does not establish causality, but it does underscore why phenotype-matched hypoglycemia reduction is a genuine safety outcome, not just a comfort measure.

Renal Impairment

Insulin clearance decreases as renal function declines, and patients with eGFR <30 mL/min/1.73m2 require dose reductions for essentially all insulin formulations including degludec. A pharmacokinetic study published in the journal Diabetes showed that insulin degludec exposure (AUC) increased by approximately 35% in patients with severe renal impairment vs. Those with normal renal function [6]. The clinical consequence is an elevated hypoglycemia risk that can be partially mitigated by dose reduction and more frequent blood glucose monitoring.

Dialysis patients are at particular risk because glucose is removed by dialysis itself, creating a post-dialysis hypoglycemia window that degludec's flat pharmacodynamic profile does not fully eliminate.

Elderly Patients (Age 65 and Older)

The Endocrine Society's Clinical Practice Guideline on diabetes management in older adults states: "In older adults with diabetes, hypoglycemia is associated with a two-fold increase in the risk of dementia and a three-fold increase in the risk of falls and fractures." [7]

Insulin degludec's lower peak-to-trough variability (coefficient of variation for day-to-day glucose-lowering effect approximately 20% vs. 82% for insulin glargine U100 in head-to-head PK/PD studies) [8] is theoretically advantageous in this group. A post-hoc DEVOTE analysis in patients aged 65 or older confirmed a preserved severe hypoglycemia benefit (rate ratio 0.61, 95% CI 0.46 to 0.81) consistent with the overall population [4].

Age alone does not increase injection-site or allergic adverse events; those remain rare across all age brackets.

Hypoglycemia Unawareness

Patients with impaired awareness of hypoglycemia (IAH) experience severe episodes at rates three to six times higher than those with intact awareness [9]. The lower nocturnal hypoglycemia rate with degludec is particularly relevant here because nocturnal events in IAH patients go undetected until they become severe. No dedicated degludec trial has enrolled exclusively IAH patients, but the SWITCH and DEVOTE nocturnal data are the most applicable evidence base.

Non-Hypoglycemic Adverse Events

Injection-Site Reactions

Lipohypertrophy and lipoatrophy occur with all subcutaneous insulin formulations. Rotating injection sites according to the ADA's Standards of Medical Care guidelines reduces their incidence [10]. In degludec phase 3 trials, injection-site reactions occurred in 3.6% of T1D patients and 1.4% of T2D patients, rates comparable to insulin glargine U100.

Injection-site pain is generally mild and transient. Persistent nodularity, visible fat changes, or erythema lasting beyond 72 hours should prompt evaluation for lipodystrophy rather than reassignment to a different injection site in the same region.

Allergic and Immune Reactions

Local allergic reactions (redness, swelling, pruritus) occur in a small minority of patients. Systemic reactions, including anaphylaxis, have been reported in post-marketing experience but are rare [1]. The Tresiba label includes a warning for generalized allergy and recommends discontinuation and treatment per standard anaphylaxis protocols if systemic reaction occurs.

Cross-reactivity between insulin analogs is uncommon but documented. Patients with known allergy to any insulin component, including metacresol (the preservative in Tresiba FlexTouch), need evaluation before initiation.

Hypokalemia

Insulin drives potassium into cells via the Na/K-ATPase pump. This effect is not unique to degludec but is clinically relevant in patients on loop diuretics, those with baseline hypokalemia, or those with heart failure. The Tresiba label includes a hypokalemia warning [1]. Routine serum potassium monitoring is appropriate during dose titration in at-risk patients.

Peripheral Edema and Weight Gain

Insulin therapy commonly causes fluid retention and weight gain. In the degludec phase 3 program, mean weight gain over 52 weeks ranged from 1.8 to 3.6 kg in T2D patients and was comparable to insulin glargine U100 in most trials. Peripheral edema was reported in approximately 1% to 2% of patients [1].

Cardiovascular and Mortality Signals

DEVOTE confirmed that insulin degludec is non-inferior to insulin glargine U100 for MACE in high-risk T2D patients. No excess cardiovascular mortality signal has emerged from post-marketing surveillance or from the FAERS database [2][4]. The FDA label carries no specific cardiovascular warning beyond the general class labeling for insulin products.

Severity Distribution Framework by Phenotype

The table below organizes the most clinically meaningful adverse events by severity tier and patient phenotype, synthesizing data from SWITCH 1, SWITCH 2, DEVOTE, the FDA label, and the pharmacokinetic literature. This framework is original to HealthRX and has been reviewed by our medical team.

| Adverse Event | Severity | T1D | T2D (Low CV Risk) | T2D (High CV Risk) | Renal Impairment | Elderly | |---|---|---|---|---|---|---| | Confirmed hypoglycemia | Moderate | Very High | Moderate | High | High | High | | Severe hypoglycemia | Severe | Moderate | Low | Moderate (40% lower vs. Glargine) | High | Moderate | | Nocturnal hypoglycemia | Moderate-Severe | High (36% lower vs. Glargine) | Moderate (36% lower vs. Glargine) | High | High | High | | Injection-site lipodystrophy | Mild | Low | Low | Low | Low | Low | | Anaphylaxis | Severe | Rare | Rare | Rare | Rare | Rare | | Hypokalemia | Moderate-Severe | Low | Low | Moderate | High | Moderate | | Weight gain | Mild | Low-Moderate | Moderate | Moderate | Moderate | Low-Moderate | | MACE | Severe | Not established | Not established | Non-inferior to glargine | Not established | Non-inferior to glargine |

Risk levels reflect relative probability within phenotype category, not absolute incidence.

Pediatric Considerations

The FDA extended Tresiba approval to children with T1D aged 1 year and older in 2019, based on the SWITCH 3 trial (N=200, ages 1 to 17 years) [11]. SWITCH 3 showed a confirmed hypoglycemia rate ratio of 0.83 (95% CI 0.70 to 0.98, P=0.026) favoring degludec over glargine U100. Nocturnal confirmed hypoglycemia rate ratio was 0.65 (95% CI 0.50 to 0.84, P=0.001) [11].

Injection-site reactions occurred at comparable rates to glargine in pediatric patients. No new safety signals emerged in the pediatric population compared with adults.

Parents and caregivers should note that degludec's prolonged action means a missed dose carries different implications than with NPH or glargine U300. A missed evening dose in a child should not be doubled the following day; the label recommends administering the missed dose as soon as it is remembered, then resuming the once-daily schedule.

Drug Interactions That Modify Adverse-Event Risk

Several drug classes amplify degludec's adverse-event potential:

• Beta-blockers: mask the tachycardia and tremor that signal hypoglycemia, raising effective severity of any hypoglycemic event
• ACE inhibitors and ARBs: may increase insulin sensitivity, lowering the threshold for hypoglycemia
• SGLT2 inhibitors: add glucose-lowering effect; combination use in T1D (off-label) raises diabetic ketoacidosis risk independent of hypoglycemia
• Corticosteroids and atypical antipsychotics: antagonize insulin action and may require dose increases that increase rebound hypoglycemia risk on discontinuation
• Loop diuretics: compound hypokalemia risk

The ADA's Standards of Medical Care in Diabetes 2024 recommends reassessing insulin doses whenever any of these agents are initiated, dose-adjusted, or discontinued [10].

Monitoring Recommendations by Risk Tier

High-Risk Phenotypes (T1D, eGFR <30, IAH)

Continuous glucose monitoring (CGM) is appropriate and supported by ADA guidelines for all adults with T1D using insulin [10]. CGM data allow detection of nocturnal hypoglycemia patterns that self-monitoring of blood glucose misses entirely. For patients with eGFR <30, weekly serum potassium and creatinine checks during the first month of degludec therapy are reasonable.

Moderate-Risk Phenotypes (T2D on Basal-Bolus, Elderly, High CV Risk)

Self-monitoring of blood glucose at fasting and two hours post-meal covers most clinically relevant events. Elderly patients who live alone or have cognitive impairment may benefit from a CGM system with a share feature that alerts a caregiver.

Lower-Risk Phenotypes (T2D on Basal-Oral Therapy)

Fasting glucose monitoring plus periodic HbA1c measurement is the minimum standard. These patients have the lowest absolute hypoglycemia incidence, but any episode severe enough to require assistance warrants re-evaluation of dose and timing.

The ADA's 2024 guideline specifies a target time-in-range of greater than 70% (70 to 180 mg/dL) and time below range of less than 4% (<70 mg/dL) for most non-pregnant adults with diabetes [10]. If a patient's CGM or structured SMBG data show time below range exceeding 4%, a degludec dose reduction is warranted before exploring other therapeutic changes.